Evidence map›Paper›PMID 39215336›Full record

ArticleTrials2024

Public perspective on potential treatment intervention harm in clinical trials-terminology and communication.

Rachel Phillips, Dongquan Bi, Beatriz Goulão, Marie Miller, Malak El-Askary, Oluyemi Fagbemi, Curie Freeborn, Maria Giammetta, Noura El Masri, Peter Flockhart and 8 more

Abstract read
In one paragraph

Article in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rachel PhillipsImperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK. r.phillips@imperial.ac.uk.ORCID http://orcid.org/0000-0002-3634-7845
Dongquan BiPragmatic Clinical Trials Unit, Centre for Evaluation and Methods, Queen Mary University of London, London, UK.
Beatriz GoulãoHealth Services Research Unit, University of Aberdeen, Aberdeen, UK.
Marie MillerImperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.
Malak El-AskaryPublic Partner, London, UK.
Oluyemi FagbemiPublic Partner, London, UK.
Curie FreebornPublic Partner, London, UK.
Maria GiammettaPublic Partner, London, UK.
Noura El MasriPublic Partner, London, UK.
Peter FlockhartPublic Partner, London, UK.
Manos KumarPublic Partner, London, UK.
Mike MelvinPublic Partner, London, UK.
Dianne MurrayPublic Partner, London, UK.
Anthony MyhillPublic Partner, London, UK.
Laila SaeidPublic Partner, London, UK.
Shanice ThomasPublic Partner, London, UK.
Graeme MacLennanHealth Services Research Unit, University of Aberdeen, Aberdeen, UK.
Victoria CorneliusImperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRandomised controlled trials (RCTs) are typically designed to determine beneficial intervention effects. In addition, an important aspect of every trial is to collect data on any potential harmful effects, with the aim of ensuring that the benefit-risk balance is appropriate. The language used by trialists to describe these potential harmful effects is inconsistent. In pharmacological trials, researchers collect adverse events; when a causal relationship is suspected adverse events are further classified as adverse reactions. Academic researchers have moved to collectively refer to these as harm outcomes; the pharmaceutical industry refer to these events as safety outcomes. In trials of complex interventions, phrases such as unintended consequences or effects are used. With the inconsistent use of terminology by researchers and the potential benefits to be gained from harmonising communications, we sought public opinion on terminology used to describe harmful effects and how these outcomes are communicated in the scientific literature, as well as in public facing material on medications.

methodsWe held two in-person public involvement meetings with public partners, in London and Aberdeen in 2023. Both meetings followed a pre-specified format. We provided a background to the topic including the information researchers collect on potential harms in clinical trials and shared examples on how this information gets presented in practice. We then discussed public partners' perspectives on terminology used and communication of intervention harm in academic journals and in public facing materials. A summary of these discussions and the main topics raised by public partners are presented.

resultsPublic partners endorsed the use of different terms for different situations, preferring the use of 'side-effect' across all contexts and reserving the use of 'harm' to indicate more severe events. Generally, public partners were happy with the type of information presented in public facing materials but discussions revealed that presentation of information on public NHS websites led to misconceptions about harm.

conclusionThis work provides a starting point on preferred terminology by patients and the public to describe potential harmful intervention effects. Whilst researchers have tried to seek agreement, public partners endorsed use of different terms for different situations. We highlight some key areas for improvement in public facing materials that are necessary to avoid miscommunication and incorrect perception of harm.

Indexed as

Public OpinionRandomized Controlled Trials as TopicTerminology as TopicCommunicationDrug-Related Side Effects and Adverse ReactionsHealth Knowledge, Attitudes, PracticeHumansResearch DesignRisk AssessmentTreatment OutcomeAdverse eventsClinical trialsHarmsPatient and public involvementPublic partners

Identifiers

PMID39215336
PMCPMC11365119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.